Investigating how MDM4 influences the development of acute myeloid leukemia (AML).
Project 2: Microenvironmental and inflammatory mechanisms in MDM4-driven AML pathogenesis.
This study is looking at how a protein called MDM4, which is found in higher amounts in many people with acute myeloid leukemia (AML), might influence the early changes in blood stem cells that lead to this type of leukemia, with the hope of finding new ways to treat or prevent the disease.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10935670 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of MDM4, a protein that is overexpressed in many patients with acute myeloid leukemia (AML), in the progression of the disease from preleukemic states. The study aims to explore how MDM4 affects the behavior of blood stem cells and their microenvironment, which may contribute to the development of AML. By using advanced mouse models and patient data, researchers will analyze the mechanisms behind the transformation of preleukemic cells into leukemia. This could provide insights into the early stages of AML and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with preleukemic conditions or those at risk of developing AML, particularly older adults.
Not a fit: Patients who are already diagnosed with advanced-stage AML or those without any preleukemic conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating AML by targeting the mechanisms involved in its progression.
How similar studies have performed: Other research has shown promising results in understanding the role of microenvironmental factors in leukemia progression, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Steidl, Ulrich — Columbia University Health Sciences
- Study coordinator: Steidl, Ulrich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.